Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Fungal Group Zygomycota01:29

Fungal Group Zygomycota

2.1K
Zygomycota, previously classified as a distinct fungal group, are primarily terrestrial, saprophytic molds that play a crucial role as decomposers. Recent phylogenetic studies have revealed that these fungi are now divided into two major clades — Mucoromycota, which includes many symbiotic species, and Zoopagomycota, which primarily consists of parasitic and pathogenic fungi. These groups exhibit distinct ecological roles and reproductive strategies while sharing key structural and...
2.1K
Antifungal Agents01:15

Antifungal Agents

53
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
53
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

716
Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
716

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pulmonary mucosa-associated lymphoid tissue lymphoma: Is gastric involvement underdiagnosed?

Cancer·2026
Same author

[Invasive mycoses in France: what are the trends?]

La Revue du praticien·2026
Same author

WHO Global Antimicrobial Resistance Surveillance System (GLASS) for monitoring bloodstream infections due to <i>Candida</i>: findings from a demonstration study.

EClinicalMedicine·2026
Same author

Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a prospective observational cohort study.

The Journal of infection·2026
Same author

Endocarditis Due to <i>Scedosporium</i> spp and <i>Lomentospora prolificans</i>: Case Series and Literature Review.

Open forum infectious diseases·2026
Same author

Non-invasive management of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.

American journal of respiratory and critical care medicine·2026

Related Experiment Video

Updated: Apr 3, 2026

Sexual Crosses with the Mucoromycete Phycomyces blakesleeanus
05:34

Sexual Crosses with the Mucoromycete Phycomyces blakesleeanus

Published on: June 6, 2025

706

Mucormycosis: New Developments into a Persistently Devastating Infection.

François Danion1, Claire Aguilar1, Emilie Catherinot1

  • 1Service de Maladies Infectieuses et tropicales, APHP-Hôpital Necker-Enfants Malades, Université Paris Descartes, Sorbonne Paris Cité, IHU Imagine, Paris, France.

Seminars in Respiratory and Critical Care Medicine
|September 24, 2015
PubMed
Summary

Mucormycosis is a dangerous fungal infection with high mortality. Early diagnosis and treatment with amphotericin B lipid formulation, surgery, and risk factor modification are crucial for survival.

More Related Videos

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
09:52

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

11.2K
Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis
08:48

Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis

Published on: March 19, 2019

7.5K

Related Experiment Videos

Last Updated: Apr 3, 2026

Sexual Crosses with the Mucoromycete Phycomyces blakesleeanus
05:34

Sexual Crosses with the Mucoromycete Phycomyces blakesleeanus

Published on: June 6, 2025

706
Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
09:52

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

11.2K
Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis
08:48

Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis

Published on: March 19, 2019

7.5K

Area of Science:

  • Mycology
  • Infectious Diseases
  • Radiology

Background:

  • Mucormycosis, a life-threatening fungal infection caused by Mucorales, is increasingly prevalent with a high mortality rate (around 50%).
  • It primarily affects patients with diabetes mellitus or immunosuppression (e.g., post-chemotherapy, transplantation).
  • Common sites include the lungs and rhino-orbito-cerebral regions.

Purpose of the Study:

  • To highlight the diagnostic challenges of mucormycosis due to overlapping features with aspergillosis.
  • To emphasize the need for prompt diagnosis and effective treatment strategies.
  • To discuss recent advancements in diagnostic tools and treatment recommendations.

Main Methods:

  • Review of clinical and radiological features, including the reversed halo sign on CT scans.
  • Discussion of emerging molecular diagnostic tools, such as quantitative polymerase chain reaction (qPCR) for Mucorales DNA detection.
  • Reference to recent clinical practice guidelines (ECIL, ECMM/ESCMID) for management.

Main Results:

  • Invasive procedures (endoscopy, biopsy) are currently necessary for definitive diagnosis.
  • Quantitative PCR shows promise for early detection of Mucorales DNA in serum.
  • The reversed halo sign on CT may suggest mucormycosis.

Conclusions:

  • Prompt diagnosis and treatment are critical for improving survival rates in mucormycosis.
  • Current recommended treatment involves amphotericin B lipid formulation, surgery, and risk factor modification.
  • Further research, including clinical trials, is needed to define the role of newer agents like isavuconazole and posaconazole formulations and to improve therapeutic success.